WO2000031247A3 - Recombinant methods and materials for producing epothilone and epothilone derivatives - Google Patents

Recombinant methods and materials for producing epothilone and epothilone derivatives Download PDF

Info

Publication number
WO2000031247A3
WO2000031247A3 PCT/US1999/027438 US9927438W WO0031247A3 WO 2000031247 A3 WO2000031247 A3 WO 2000031247A3 US 9927438 W US9927438 W US 9927438W WO 0031247 A3 WO0031247 A3 WO 0031247A3
Authority
WO
WIPO (PCT)
Prior art keywords
epothilone
materials
derivatives
recombinant methods
producing
Prior art date
Application number
PCT/US1999/027438
Other languages
French (fr)
Other versions
WO2000031247A2 (en
Inventor
Bryan Julien
Leonard Katz
Chaitan Khosla
Li Tang
Rainer Ziermann
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99960500A priority Critical patent/EP1135470A2/en
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Priority to CNB998156787A priority patent/CN100381566C/en
Priority to AU17377/00A priority patent/AU768220B2/en
Priority to IL14306999A priority patent/IL143069A0/en
Priority to NZ511722A priority patent/NZ511722A/en
Priority to CA002350189A priority patent/CA2350189A1/en
Priority to JP2000584057A priority patent/JP4662635B2/en
Priority to US09/560,367 priority patent/US6410301B1/en
Publication of WO2000031247A2 publication Critical patent/WO2000031247A2/en
Publication of WO2000031247A3 publication Critical patent/WO2000031247A3/en
Priority to IL143069A priority patent/IL143069A/en
Priority to US10/191,694 priority patent/US7067286B2/en
Priority to US11/231,735 priority patent/US20060223151A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Abstract

Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) of sorangium cellulosum are used to express recombinant PKS genes in host cells for the production of epithilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants.
PCT/US1999/027438 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives WO2000031247A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002350189A CA2350189A1 (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives
CNB998156787A CN100381566C (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and eopthilone derivatives
AU17377/00A AU768220B2 (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives
IL14306999A IL143069A0 (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives
NZ511722A NZ511722A (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives
EP99960500A EP1135470A2 (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives
JP2000584057A JP4662635B2 (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives
US09/560,367 US6410301B1 (en) 1998-11-20 2000-04-28 Myxococcus host cells for the production of epothilones
IL143069A IL143069A (en) 1998-11-20 2001-05-10 Recombinant methods and materials for producing epothilone and epothilone derivatives
US10/191,694 US7067286B2 (en) 1998-11-20 2002-07-08 Cystobacterineae host cells containing heterologous PKS genes for the synthesis of polykedtides
US11/231,735 US20060223151A1 (en) 1998-11-20 2005-09-20 Production of polyketides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10940198P 1998-11-20 1998-11-20
US60/109,401 1998-11-20
US11938699P 1999-02-10 1999-02-10
US60/119,386 1999-02-10
US12262099P 1999-03-03 1999-03-03
US60/122,620 1999-03-03
US13056099P 1999-04-22 1999-04-22
US60/130,560 1999-04-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/443,501 Continuation-In-Part US6303342B1 (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilones C and D

Publications (2)

Publication Number Publication Date
WO2000031247A2 WO2000031247A2 (en) 2000-06-02
WO2000031247A3 true WO2000031247A3 (en) 2000-12-07

Family

ID=27493695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027438 WO2000031247A2 (en) 1998-11-20 1999-11-19 Recombinant methods and materials for producing epothilone and epothilone derivatives

Country Status (10)

Country Link
US (7) US6303342B1 (en)
EP (1) EP1135470A2 (en)
JP (2) JP4662635B2 (en)
KR (3) KR20070087132A (en)
CN (1) CN100381566C (en)
AU (1) AU768220B2 (en)
CA (1) CA2350189A1 (en)
IL (2) IL143069A0 (en)
NZ (1) NZ511722A (en)
WO (1) WO2000031247A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100538095B1 (en) 1996-11-18 2005-12-21 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6399789B1 (en) 1996-12-18 2002-06-04 Kosan Biosciences, Inc. Multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
DE19826988A1 (en) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
DE19846493A1 (en) * 1998-10-09 2000-04-13 Biotechnolog Forschung Gmbh DNA sequence coding for products involved in the biosynthesis of polyketide or heteropolyketide compounds, especially epothilone
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
HUP0200296A2 (en) * 1998-12-23 2002-05-29 Bristol Myers Squibb Co Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
ATE331028T1 (en) * 1999-04-16 2006-07-15 Kosan Biosciences Inc MULTI-PLASMID PROCESS FOR PRODUCING LARGE LIBRARIES OF POLYKETIDES AND NON-RIBOSOMAL PEPTIDES
WO2001031049A2 (en) * 1999-10-25 2001-05-03 Kosan Biosciences, Inc. Production of polyketides
IL148934A0 (en) * 1999-10-27 2002-09-12 Kosan Biosciences Inc Heterologous production of polyketides
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
AU2001295195B2 (en) * 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
WO2001092991A2 (en) 2000-05-30 2001-12-06 Kosan Biosciences, Inc. Design of polyketide synthase genes
JP2004516011A (en) * 2000-07-25 2004-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド Fermentation process for epothilone
AU2001283275A1 (en) * 2000-08-09 2002-02-18 Kosan Biosciences, Inc. Bio-intermediates for use in the chemical synthesis of polyketides
WO2002032916A2 (en) * 2000-09-25 2002-04-25 Kosan Biosciences, Inc. Sixteen-membered macrolide compounds
US7257562B2 (en) 2000-10-13 2007-08-14 Thallion Pharmaceuticals Inc. High throughput method for discovery of gene clusters
US20030077759A1 (en) * 2000-12-28 2003-04-24 Zhihao Hu Plasmids for polyketide production
PT1353668E (en) 2001-01-25 2008-06-30 Bristol Myers Squibb Co Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer
SK8552003A3 (en) 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1368030A1 (en) 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
SK11082003A3 (en) 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Combination of epotilone analogues and chemotherapeutic agents for treatment of proliferative diseases
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20070203346A1 (en) * 2001-04-30 2007-08-30 Oregon State University Method for synthesizing epothilones and epothilone analogs
MXPA03010909A (en) 2001-06-01 2004-02-17 Bristol Myers Squibb Co Epothilone derivatives.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
WO2003014311A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Methods for altering polyketide synthase genes
AU2002363803A1 (en) * 2001-11-15 2003-05-26 Kosan Biosciences, Inc. Method for making epothilone compounds by bioconversion with microorganisms
US7189549B2 (en) * 2002-06-14 2007-03-13 Kosan Biosciences, Inc. Recombinant polynucleotides encoding pro-geldanamycin producing polyketide synthase and accessory proteins, and uses thereof
EP2030618A3 (en) 2002-01-14 2009-03-11 Novartis AG Combinations comprising epothilones and anti-metabolites
CN1639319B (en) * 2002-02-25 2010-04-28 高山生物科学股份有限公司 Secondary metabolite congener distribution modulation
EP1483251B1 (en) 2002-03-12 2009-12-23 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
EP1575556A2 (en) * 2002-05-20 2005-09-21 Kosan Biosciences, Inc. Methods to administer epothilone d
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003258978A1 (en) 2002-06-28 2004-01-19 Kosan Biosciences, Inc. Recombinant genes for polyketide modifying enzymes
WO2004015088A2 (en) * 2002-08-13 2004-02-19 Kosan Biosciences, Inc. Transposon-based transformation system
AU2003265608A1 (en) * 2002-08-21 2004-03-11 Kosan Biosciences, Inc. Myxococcus xanthus bacteriophage mx9 transformation and integration system
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1767535B1 (en) 2002-08-23 2009-12-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
KR101406635B1 (en) 2002-09-23 2014-06-11 브리스톨-마이어스 스큅 컴퍼니 Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
CN101177425B (en) * 2003-01-28 2012-07-18 北京华昊中天生物技术有限公司 Novel epothilones compound as well as preparation method and use thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
PL2253614T3 (en) 2004-04-07 2013-03-29 Novartis Ag Inhibitors of IAP
US7595187B2 (en) * 2004-11-12 2009-09-29 Wyeth Elaiophylin biosynthetic gene cluster
US20060211736A1 (en) * 2005-01-13 2006-09-21 Wisconsin Alumni Research Foundation Glutarimide-containing polyketide analogs and methods thereof
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
KR100681811B1 (en) * 2005-03-15 2007-02-12 성균관대학교산학협력단 Method for Preparing a Useful Secondary Metabolite by Effective Elimination of Biological By-Products
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0616755A2 (en) 2005-09-27 2011-06-28 Novartis Ag carboxyamine compounds and methods of using them
AU2006314444C1 (en) 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CN102671196B (en) 2006-04-05 2014-12-03 诺华股份有限公司 Combinations of therapeutic agents for treating cancer
EP2314297A1 (en) 2006-04-05 2011-04-27 Novartis AG Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California Combination therapy for treatment of cancer
KR20090007635A (en) 2006-05-09 2009-01-19 노파르티스 아게 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
JP5419685B2 (en) 2006-05-16 2014-02-19 ファーマサイエンス・インコーポレイテッド IAPBIR domain binding protein
JP2010504933A (en) 2006-09-29 2010-02-18 ノバルティス アーゲー Pyrazolopyrimidines as PI3K lipid kinase inhibitors
EP2359818A1 (en) 2007-02-15 2011-08-24 Novartis AG Combination of LBH589 with HSP 90 inhibitors for treating cancer
US9115359B2 (en) * 2007-04-02 2015-08-25 Newsouth Innovations Pty Limited Methods for producing secondary metabolites
KR100901164B1 (en) * 2007-07-16 2009-06-04 성균관대학교산학협력단 Epothilone Producing Strain Transformed with Heterologous Propionyl-CoA Synthetase Gene and Method for Preparing Epothilone Using the Same
MX2010010525A (en) 2008-03-24 2010-10-25 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors.
NZ588069A (en) 2008-03-26 2012-06-29 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
US8569023B2 (en) * 2008-03-28 2013-10-29 The Regents Of The University Of California Producing dicarboxylic acids using polyketide synthases
DK2276485T3 (en) 2008-04-24 2014-10-13 Bristol Myers Squibb Co USE OF EPOTHILON D IN TREATMENT OF TAU-ASSOCIATED DISEASES, INCLUDING ALZHEIMER'S DISEASE
JP2011519860A (en) * 2008-04-29 2011-07-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Biofuel production using polyketide synthase
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
EP2391366B1 (en) 2009-01-29 2012-11-28 Novartis AG Substituted benzimidazoles for the treatment of astrocytomas
SI2445903T1 (en) 2009-06-26 2014-07-31 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (en) 2009-08-12 2012-02-29 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
KR20120089463A (en) 2009-08-20 2012-08-10 노파르티스 아게 Heterocyclic oxime compounds
BR112012008075A2 (en) 2009-08-26 2016-03-01 Novartis Ag tetrasubstituted heteroaryl compounds and their use as mdm2 and / or mdm4 modulators
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
EP3351558B1 (en) 2009-11-13 2020-03-11 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
CA2781218A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (en) 2009-12-22 2015-09-29 Novartis Ag ISOQUINOLINONES AND REPLACED QUINAZOLINONES
BR112012020113A2 (en) 2010-02-12 2016-06-07 Pharmascience Inc iap bir domain binding compounds
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treatment of autoimmune and other diseases
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
US8852902B2 (en) 2010-11-22 2014-10-07 The Regents Of The University Of California Producing a trimethylpentanoic acid using hybrid polyketide synthases
MX2013008062A (en) 2011-01-28 2013-08-09 Amyris Inc Gel-encapsulated microcolony screening.
JP2014505088A (en) 2011-02-10 2014-02-27 ノバルティス アーゲー [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
CN103649073B (en) 2011-04-28 2016-04-13 诺瓦提斯公司 17 α-hydroxylase/C 17,20-lyase inhibitor
KR20140032438A (en) 2011-05-13 2014-03-14 아미리스 인코퍼레이티드 Methods and compositions for detecting microbial production of water-immiscible compounds
IN2014DN00123A (en) 2011-06-09 2015-05-22 Novartis Ag
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
KR20140025530A (en) 2011-06-27 2014-03-04 노파르티스 아게 Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
BR112014006223A8 (en) 2011-09-15 2018-01-09 Novartis Ag 6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination
JP5992054B2 (en) 2011-11-29 2016-09-14 ノバルティス アーゲー Pyrazolopyrrolidine compound
EA025322B1 (en) 2011-12-22 2016-12-30 Новартис Аг Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
CN104125953A (en) 2011-12-23 2014-10-29 诺华股份有限公司 Compounds for inhibiting interaction of bcl2 with binding partners
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503515A (en) 2011-12-23 2015-02-02 ノバルティス アーゲー COMPOUND AND COMPOSITION FOR INHIBITING BCL2 AND BINDING PARTY INTERACTION
WO2013096055A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
WO2013171640A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PL2900637T3 (en) 2012-05-15 2018-01-31 Novartis Ag Thiazole or imidazole substituted pyrimidine, pyridine and pyrazine amide derivatives and related compounds as abl1, abl2 and bcr-abl1 inhibitors for the treatment of cancer, specific viral infections and specific cns disorders
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CU24265B1 (en) 2012-05-15 2017-07-04 Novartis Ag COMPOUNDS DERIVED FROM BENZAMIDE TO INHIBIT THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1, USEFUL IN THE TREATMENT OF CANCER
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
EP2861256B1 (en) 2012-06-15 2019-10-23 The Brigham and Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
US10090498B2 (en) 2012-06-24 2018-10-02 SeeScan, Inc. Modular battery pack apparatus, systems, and methods including viral data and/or code transfer
AU2013299608B2 (en) 2012-08-07 2019-02-21 Amyris, Inc. Methods for stabilizing production of acetyl-coenzyme a derived compounds
PE20150998A1 (en) 2012-10-02 2015-06-29 Epitherapeutics Aps HISTONE DEMETILASE INHIBITORS
TW201422625A (en) 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
PL2961736T3 (en) 2013-02-27 2018-08-31 Gilead Sciences, Inc. Inhibitors of histone demethylases
MX364748B (en) 2013-03-15 2019-05-06 Amyris Inc Use of phosphoketolase and phosphotransacetylase for production of acetyl-coenzyme a derived compounds.
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
US10563229B2 (en) 2013-08-07 2020-02-18 Amyris, Inc. Methods for stabilizing production of acetyl-coenzyme a derived compounds
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
US10233431B2 (en) 2014-02-26 2019-03-19 The Regents Of The University Of California Producing 3-hydroxycarboxylic acid and ketone using polyketide synthases
JP6517319B2 (en) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ Substituted heteroaryl compounds and methods of use
WO2015153498A1 (en) 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibitors of histone demethylases
BR112016022499A2 (en) 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd SUPRAMOLECULAR COMBINATORY THERAPEUTIC PRODUCTS
KR101606635B1 (en) * 2014-06-02 2016-03-28 이화여자대학교 산학협력단 Expression cassettes and their use
KR101601424B1 (en) * 2014-06-02 2016-03-09 이화여자대학교 산학협력단 Expression vector and its use
AU2015306662A1 (en) 2014-08-27 2017-03-09 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
BR112017027970A2 (en) 2015-06-25 2018-08-28 Amyris, Inc. maltose-dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in the production of non-catabolic compounds
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CN108658949B (en) * 2018-06-29 2021-05-25 云南大学 Compound used as antitumor drug and production method thereof
FR3087650B1 (en) 2018-10-31 2021-01-29 Bio Even FLAVINE ADENINE DINUCLEOTIDE (FAD) FOR USE FOR THE PREVENTION AND / OR TREATMENT OF CANCER
CN113969255A (en) * 2020-07-24 2022-01-25 北京华昊中天生物医药股份有限公司 Recombinant bacterium for producing de-epoxidized epothilone B and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022461A1 (en) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
WO1999066028A2 (en) * 1998-06-18 1999-12-23 Novartis Ag Genes for the biosynthesis of epothilones
WO2000022139A2 (en) * 1998-10-09 2000-04-20 Bristol-Myers Squibb Company Dna sequences for enzymatic synthesis of polyketide or heteropolyketide compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5252474A (en) 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
KR0159766B1 (en) 1989-10-16 1998-12-01 후지사와 토모키치로 Hair revitalizing agent
GB8925797D0 (en) 1989-11-15 1990-01-04 Fisons Plc Compositions
US5824513A (en) 1991-01-17 1998-10-20 Abbott Laboratories Recombinant DNA method for producing erythromycin analogs
WO1993013663A1 (en) 1992-01-17 1993-07-22 Abbott Laboratories Method of directing biosynthesis of specific polyketides
PT501921E (en) 1991-03-01 2001-12-28 Syngenta Participations Ag PROCESS FOR THE GENETIC MANIPULATION OF MIXOBACTERIAS
DE4138042C2 (en) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their production processes and agents containing these compounds
US5264355A (en) 1992-07-02 1993-11-23 Merck & Co., Inc. Methlating enzyme from streptomyces MA6858
AU678058B2 (en) 1993-09-20 1997-05-15 John Innes Centre Recombinant production of novel polyketides
US5712146A (en) 1993-09-20 1998-01-27 The Leland Stanford Junior University Recombinant combinatorial genetic library for the production of novel polyketides
US6066721A (en) 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
US5672491A (en) 1993-09-20 1997-09-30 The Leland Stanford Junior University Recombinant production of novel polyketides
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
NZ313383A (en) 1995-07-06 1999-08-30 Univ Leland Stanford Junior Cell-free synthesis of polyketides using pks (polyketide synthase)
DE69636195T2 (en) 1995-10-13 2007-03-29 President And Fellows Of Harvard College, Cambridge PHOSPHOPANTETHENYL TRANSFERASES AND ITS USES
DK1186606T4 (en) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilone derivatives, their preparation and use
US5776735A (en) 1995-12-04 1998-07-07 Pfizer Inc. Process for dienone macrolides
US5998194A (en) 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
US5783431A (en) 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6033883A (en) 1996-12-18 2000-03-07 Kosan Biosciences, Inc. Production of polyketides in bacteria and yeast
JP2001524829A (en) 1997-04-30 2001-12-04 コーサン バイオサイエンシーズ，インコーポレイテッド Combinatorial polyketide library generated using modular PKS gene cluster as scaffold
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
IL133716A0 (en) 1997-07-10 2001-04-30 Kosan Biosciences Inc Production of polyketides in plants
EP1847540A1 (en) 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique
DE19741899A1 (en) 1997-09-22 1999-03-25 Hahl Erwin Gmbh Synthetic bristles for moving brushes for automatic car wash
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6090601A (en) 1998-01-23 2000-07-18 Kosan Bioscience Sorangium polyketide synthase
US6280999B1 (en) * 1998-01-23 2001-08-28 Kosan Bioscience Sorangium polyketide synthases and encoding DNA therefor
MY125921A (en) 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
DE19804673A1 (en) 1998-02-06 1999-08-12 Studiengesellschaft Kohle Mbh Process for the preparation of macrocyclic products by ring-closing diine metathesis
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
DE69927790T2 (en) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research SYNTHESIS OF EPOTHILONES, ITS INTERMEDIATE PRODUCTS AND ANALOGICAL COMPOUNDS
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
DE19826988A1 (en) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
WO2000000485A1 (en) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
WO2000001838A2 (en) 1998-07-02 2000-01-13 The Board Of Regents Of The Leland Stanford Junior University Methods for making polyketides
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
AU2001295195B2 (en) 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
WO2002080846A2 (en) 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP3318214B1 (en) 2017-04-21 2020-04-15 Siemens Healthcare GmbH Medical imaging device with smartglasses and method for supporting a person using a medical imaging device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022461A1 (en) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
WO1999066028A2 (en) * 1998-06-18 1999-12-23 Novartis Ag Genes for the biosynthesis of epothilones
WO2000022139A2 (en) * 1998-10-09 2000-04-20 Bristol-Myers Squibb Company Dna sequences for enzymatic synthesis of polyketide or heteropolyketide compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOU T. C. ET AL.: "DESOXYEPITHILONE B: AN EFFICACIOUS MICROTUBULE-TARGETED ANTITUMOR AGENT WITH A PROMISING IN VIVO PROFILE RELATIVE TO EPOTHILONE B.", PROC. NATL. ACAD. SCI. USA, vol. 95, no. 16, 4 August 1998 (1998-08-04), pages 9642 - -7, XP000910107 *
MOLNÁR I. ET AL.: "The biosynthetic gene cluster for ... epothilones A and B from Sorangium cellulosum So ce90.", CHEMISTRY & BIOLOGY VOL 7 NO 2, 5 January 2000 (2000-01-05), pages 97 - 109, XP000904734 *
TANG, L. ET AL.: "Cloning and heterologous expression of the epithilone gene cluster.", SCIENCE, vol. 287, 28 January 2000 (2000-01-28), pages 640 - 42, XP000213584 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Also Published As

Publication number Publication date
KR20070087132A (en) 2007-08-27
US7402421B2 (en) 2008-07-22
US6921650B1 (en) 2005-07-26
NZ511722A (en) 2004-05-28
EP1135470A2 (en) 2001-09-26
WO2000031247A2 (en) 2000-06-02
US20090170172A1 (en) 2009-07-02
US6583290B1 (en) 2003-06-24
US7732186B2 (en) 2010-06-08
KR20060124789A (en) 2006-12-05
US20040253697A1 (en) 2004-12-16
CN100381566C (en) 2008-04-16
CA2350189A1 (en) 2000-06-02
US7129071B1 (en) 2006-10-31
US6303342B1 (en) 2001-10-16
KR100716272B1 (en) 2007-05-09
AU768220B2 (en) 2003-12-04
US6858411B1 (en) 2005-02-22
JP2007097595A (en) 2007-04-19
IL143069A (en) 2008-06-05
IL143069A0 (en) 2002-04-21
JP2002530107A (en) 2002-09-17
JP4662635B2 (en) 2011-03-30
KR20010093103A (en) 2001-10-27
CN1333820A (en) 2002-01-30
AU1737700A (en) 2000-06-13
KR100851418B1 (en) 2008-08-08

Similar Documents

Publication Publication Date Title
WO2000031247A3 (en) Recombinant methods and materials for producing epothilone and epothilone derivatives
WO2000026349A3 (en) Recombinant oleandolide polyketide synthase
WO2002042418A3 (en) 3-hydroxypropionic acid and other organic compounds
HK1054967A1 (en) Method of amplifying nucleic acid by using double-stranded nucleic acid as template
WO2004031376A3 (en) Sesquiterpene synthases and methods of use
WO2002026933A3 (en) Isoprenoid production
WO2002018587A1 (en) Process for producing biopterins
WO2005012487A3 (en) Compositions and methods for preparing short rna molecules and other nucleic acids
WO2003046173A1 (en) siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
AU2001269837A1 (en) Process for producing microfluidic articles
WO2001020035A3 (en) Methods and compositions for linear isothermal amplification of polynucleotide sequences
WO2004047742A3 (en) Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
AU2003211058A1 (en) RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO1999066028A3 (en) Genes for the biosynthesis of epothilones
WO2003102214A3 (en) Method for efficient rna interference in mammalian cells
WO2002097062A3 (en) Recombinant narbonolide polyketide synthase
WO2006072078A3 (en) Bioproduction of astaxanthin using mutant carotenoid ketolase and cartonenoid hydroxylase genes
WO2002103046A3 (en) Happier mapping
WO1999061599A3 (en) Recombinant narbonolide polyketide synthase
FR2804971B1 (en) DNA ENCODING ACETOHYDROXYACIDE SYNTHASE, BACTERIA CONTAINING SAME, AND METHOD FOR PRODUCING L-VALINE BY CULTURING THE SAME
WO2003072798A3 (en) Method for generating amplified rna
WO2005052163A3 (en) Sesquiterpene synthases from patchouli
WO2000004166A3 (en) Plant cellulose synthases
WO2001077306A3 (en) Plant raffinose saccharide biosynthetic enzymes
AU2002219140A1 (en) Modulating gene expression in insects by using double-stranded rna (dsrna)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99815678.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 17377

Country of ref document: AU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09560367

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU IL IS JP KG KP KR LC LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU IL IS JP KG KP KR LC LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2350189

Country of ref document: CA

Ref document number: 2350189

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 143069

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999960500

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 511722

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2000 584057

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005097

Country of ref document: MX

Ref document number: 1020017006398

Country of ref document: KR

Ref document number: 17377/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999960500

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017006398

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10191694

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 17377/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11231735

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1020017006398

Country of ref document: KR